$ATAI news
The latest ATAI stock news: headlines, filings, AI summaries and sentiment for $ATAI, updated around the clock.
- Eli Lilly Reports 39% Revenue Growth Driven by Increased Sales Volume
- Revenue Comparison: Eli Lilly's GLP-1 Growth vs. Bristol Myers Squibb's Steady Performance
- Wells Fargo's Net Interest Margin Shows Slight Improvement; Eli Lilly Receives Buy Rating Amid Acquisition Strategy
- Atea Pharmaceuticals Reports Positive Phase 3 Trial Results for Hepatitis C Treatment
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal; Cathie Wood Favors Competitor Compass Pathways
- Eli Lilly Acquires AtaiBeckley for $2.8 Billion in Expansion into Mental Health Therapies
- Eli Lilly Acquires AtaiBeckley to Expand Mental Health Portfolio
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal; Cathie Wood Shifts Focus to Compass Pathways
- Eli Lilly Acquires AtaiBeckley for $2.8 Billion to Expand Neuroscience Portfolio
- Eli Lilly Acquires AtaiBeckley for $2.8 Billion to Expand Neuroscience Portfolio
- Eli Lilly Acquires Psychedelic Medicine Biotech AtaiBeckley
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion in Psychedelic Drug Development
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion, Expanding Psychedelic Drug Portfolio
- AtaiBeckley Stock Surges After Acquisition Agreement with Eli Lilly
- AtaiBeckley (ATAI) Reaches Four-Year High Following $3.8B Merger Agreement with Eli Lilly
- AtaiBeckley Surges Following Eli Lilly's Acquisition Offer Worth Up to $3.8 Billion
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal
- Eli Lilly to Acquire Psychedelic Drugmaker AtaiBeckley for $2.8 Billion
- GH Research Gains on Potential Acquisition Talks Involving Eli Lilly and Atai Life Sciences
- AtaiBeckley Shares Rise on Reports of Potential Acquisition by Eli Lilly
- AtaiBeckley shares surge amid reported acquisition talks with Eli Lilly
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion in Landmark Psychedelic Medicine Deal
- Weekly Press Release Roundup: Olive Garden Returns Pasta Pass, KKR Invests in Thomson Reuters Print Business
- AtaiBeckley Stock Surges After Acquisition Agreement with Eli Lilly
- AtaiBeckley Surges on Eli Lilly Acquisition Worth Up to $3.8 Billion
- Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
- Lilly to Acquire AtaiBeckley for Up to $3.8 Billion
- Stocks Making Significant Premarket Moves: UnitedHealth, TSMC, GE Aerospace, J.B. Hunt and Others
- Eli Lilly Acquires Psychedelics Maker AtaiBeckley for $2.8 Billion
- AtaiBeckley Shares Rise on Potential Acquisition by Eli Lilly
- AtaiBeckley Completes Dosing in Phase 2b Trial for VLS-01 Treatment of Depression
- AtaiBeckley Director Sells $496K Worth of Shares Amid Significant Stock Gains
- AtaiBeckley Reports Q1 Financial Results
- Trump's Executive Order on Psychedelics Seen as Validation for Investors
- Trump Signs Executive Order to Accelerate Psychedelic Research and Regulation
- Guggenheim Raises Price Target for AtaiBeckley Inc (ATAI)
- AtaiBeckley Stock Surges After Trump Orders Accelerated Review of Psychedelic Treatments
- Trump Fast-Tracks Psychedelic Treatments, Boosting Biotech Stocks
- Psychedelic Stocks Rise Following Trump's Order to Accelerate PTSD Research
- Trump Signs Executive Order to Expedite Psychedelic Drug Research and Treatments